Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
Debdulal Chakraborty,1 Aniruddha Maiti,2 Jay U Sheth,3 Subhendu Boral,1 Soumen Mondal,1 Krishnendu Nandi,2 Tushar Sinha,1 Arnab Das1 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of Vitreoretinal Services, Netralayam Super Speciality Eye Care Ce...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1fa860a04c1541748bde2aa5e468392f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1fa860a04c1541748bde2aa5e468392f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1fa860a04c1541748bde2aa5e468392f2021-12-02T19:12:05ZBrolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study1177-5483https://doaj.org/article/1fa860a04c1541748bde2aa5e468392f2021-09-01T00:00:00Zhttps://www.dovepress.com/brolucizumab-in-neovascular-age-related-macular-degeneration--indian-r-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Debdulal Chakraborty,1 Aniruddha Maiti,2 Jay U Sheth,3 Subhendu Boral,1 Soumen Mondal,1 Krishnendu Nandi,2 Tushar Sinha,1 Arnab Das1 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of Vitreoretinal Services, Netralayam Super Speciality Eye Care Centre, Kolkata, West Bengal, India; 3Department of Vitreoretinal Services, Surya Eye Institute and Research Center, Mumbai, Maharashtra, IndiaCorrespondence: Debdulal ChakrabortyDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, IndiaTel +91 9433059923Email devdc.dr@gmail.comPurpose: To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions.Patients and Methods: This was a multicenter, retrospective chart review of 94 eyes of 94 patients with nAMD (treatment-naïve and switch-therapy) undergoing brolucizumab therapy. Re-treatment as per pro-re-nata protocol was performed based on fixed visual and tomographic criteria. The main outcome measures were changes in the best-corrected visual acuity (BCVA), intraretinal fluid (IRF), subretinal fluid (SRF), central subfield thickness (CST), and pigment epithelial detachment (PED) along with safety analysis.Results: Of the 94 eyes, 20 eyes (21.3%) were treatment-naïve, whereas the rest 74 eyes (78.7%) underwent switch therapy. One hundred and twenty-six injections were given over a mean follow-up of 7.3 ± 2.2 (range 5– 30) weeks. The BCVA improved significantly from 0.82 ± 0.5 LogMAR at baseline to 0.66 ± 0.5 LogMAR at the final visit (p < 0.0001). Significant reduction in CST was simultaneously noted (Baseline: 408.45 ± 65.63 μm; Final: 281.14 ± 37.74 μm; p < 0.0001). On qualitative analysis, resolution of subretinal fluid (SRF), intraretinal fluid (IRF), and pigment epithelial detachment (PED) was observed in 15.5%, 39.29%, and 23.81% of the eyes, respectively. The mean interval of repeat injection was 10.2 ± 2.1 weeks. Three episodes of ocular adverse drug reaction were reported, including two patients developing subretinal hemorrhage while one having a retinal pigment epithelial (RPE) tear. Notably, no intraocular inflammation (IOI) was seen in any of the eyes, and no systemic side effects were identified.Conclusion: In a real-world scenario, brolucizumab therapy is efficacious and safe in the management of nAMD over the short term. Further long-term studies are warranted to validate these findings. Additionally, lack of ocular inflammation after 126 brolucizumab injections in our Indian data is peculiar and underlines the necessity to explore the role of race and genetics in predisposing to/safeguarding against brolucizumab-related IOIs.Keywords: brolucizumab, inflammation, age-related macular degenerationChakraborty DMaiti ASheth JUBoral SMondal SNandi KSinha TDas ADove Medical Pressarticlebrolucizumabinflammationage related macular degenerationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3787-3795 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
brolucizumab inflammation age related macular degeneration Ophthalmology RE1-994 |
| spellingShingle |
brolucizumab inflammation age related macular degeneration Ophthalmology RE1-994 Chakraborty D Maiti A Sheth JU Boral S Mondal S Nandi K Sinha T Das A Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study |
| description |
Debdulal Chakraborty,1 Aniruddha Maiti,2 Jay U Sheth,3 Subhendu Boral,1 Soumen Mondal,1 Krishnendu Nandi,2 Tushar Sinha,1 Arnab Das1 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of Vitreoretinal Services, Netralayam Super Speciality Eye Care Centre, Kolkata, West Bengal, India; 3Department of Vitreoretinal Services, Surya Eye Institute and Research Center, Mumbai, Maharashtra, IndiaCorrespondence: Debdulal ChakrabortyDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, IndiaTel +91 9433059923Email devdc.dr@gmail.comPurpose: To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions.Patients and Methods: This was a multicenter, retrospective chart review of 94 eyes of 94 patients with nAMD (treatment-naïve and switch-therapy) undergoing brolucizumab therapy. Re-treatment as per pro-re-nata protocol was performed based on fixed visual and tomographic criteria. The main outcome measures were changes in the best-corrected visual acuity (BCVA), intraretinal fluid (IRF), subretinal fluid (SRF), central subfield thickness (CST), and pigment epithelial detachment (PED) along with safety analysis.Results: Of the 94 eyes, 20 eyes (21.3%) were treatment-naïve, whereas the rest 74 eyes (78.7%) underwent switch therapy. One hundred and twenty-six injections were given over a mean follow-up of 7.3 ± 2.2 (range 5– 30) weeks. The BCVA improved significantly from 0.82 ± 0.5 LogMAR at baseline to 0.66 ± 0.5 LogMAR at the final visit (p < 0.0001). Significant reduction in CST was simultaneously noted (Baseline: 408.45 ± 65.63 μm; Final: 281.14 ± 37.74 μm; p < 0.0001). On qualitative analysis, resolution of subretinal fluid (SRF), intraretinal fluid (IRF), and pigment epithelial detachment (PED) was observed in 15.5%, 39.29%, and 23.81% of the eyes, respectively. The mean interval of repeat injection was 10.2 ± 2.1 weeks. Three episodes of ocular adverse drug reaction were reported, including two patients developing subretinal hemorrhage while one having a retinal pigment epithelial (RPE) tear. Notably, no intraocular inflammation (IOI) was seen in any of the eyes, and no systemic side effects were identified.Conclusion: In a real-world scenario, brolucizumab therapy is efficacious and safe in the management of nAMD over the short term. Further long-term studies are warranted to validate these findings. Additionally, lack of ocular inflammation after 126 brolucizumab injections in our Indian data is peculiar and underlines the necessity to explore the role of race and genetics in predisposing to/safeguarding against brolucizumab-related IOIs.Keywords: brolucizumab, inflammation, age-related macular degeneration |
| format |
article |
| author |
Chakraborty D Maiti A Sheth JU Boral S Mondal S Nandi K Sinha T Das A |
| author_facet |
Chakraborty D Maiti A Sheth JU Boral S Mondal S Nandi K Sinha T Das A |
| author_sort |
Chakraborty D |
| title |
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study |
| title_short |
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study |
| title_full |
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study |
| title_fullStr |
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study |
| title_full_unstemmed |
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study |
| title_sort |
brolucizumab in neovascular age-related macular degeneration – indian real-world experience: the braille study |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/1fa860a04c1541748bde2aa5e468392f |
| work_keys_str_mv |
AT chakrabortyd brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT maitia brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT shethju brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT borals brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT mondals brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT nandik brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT sinhat brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy AT dasa brolucizumabinneovascularagerelatedmaculardegenerationndashindianrealworldexperiencethebraillestudy |
| _version_ |
1718377038988967936 |